Arcus Initial Data From Study Of Casdatifan Plus Cabozantinib Showed Nearly 50% Response

 

Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor, showed a confirmed overall response rate (ORR) of 46% in patients who reached a minimum of 12 weeks (two scans) of follow-up

The combination had a manageable safety profile, and there was no meaningful overlapping toxicity for the two drugs

These data support the initiation of PEAK-1, a Phase 3 study that will evaluate casdatifan plus cabozantinib in immunotherapy-experienced clear cell renal cell carcinoma (ccRCC) patients, and eVOLVE-RCC02, a Phase 1b/3 study in first-line ccRCC patients, both of which will begin shortly

Arcus will host a conference call to discuss these data at 5:00 AM PT / 7:00 AM CT on Monday, June 2, 2025

https://www.stocktitan.net/news/RCUS/initial-data-from-the-arc-20-study-of-casdatifan-plus-cabozantinib-gbr84ukapp4r.html